Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
R&D Expense Growth
12.75%
Quarterly · Period ending:
LCTX R&D Expense Growth
Latest reported12.75%period ending
Latest reported12.75%period ending
LCTX Quarterly R&D Growth (QoQ) (0.00% → 12.75%)
Latest values, visible window
High-resolution chart · PNG
LCTX r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 12.7539% | |
| -48.604% | |
| 151.8496% | |
| 5.3123% | |
| -0.2569% | |
| -9.0272% | |
| 7.947% | |
| 10.5649% | |
| -4.0161% | |
| -22.8704% | |
| 3.5552% | |
| -3.4082% | |
| -7.4552% | |
| 1.9737% | |
| 14.2539% | |
| 8.7826% | |
| 10.5087% | |
| -87.9409% | |
| 781.4657% | |
| -4.0942% | |
| -13.6417% | |
| 30.188% | |
| -26.8929% | |
| 27.1301% | |
| -15.9928% | |
| -4.2169% | |
| -18.2841% | |
| -18.51% | |
| 5.5231% | |
| 31.2434% | |
| -22.5727% | |
| -23.2148% | |
| 7.1272% | |
| 26.3572% | |
| -28.4212% | |
| 4.6404% | |
| -3.4339% | |
| -7.4005% | |
| 9.2027% | |
| -28.1495% | |
| -34.9206% | |
| 7.3976% | |
| 11.8517% | |
| 26.206% | |
| -2.837% | |
| -17.3247% | |
| 27.6236% | |
| -2.6957% | |
| 8.0394% | |
| -8.8354% | |
| 43.1354% | |
| 16.4738% | |
| 2.5004% | |
| 12.5636% | |
| 5.4518% | |
| -1.5159% | |
| 10.4493% | |
| 1.2484% | |
| 19.7796% | |
| 4.883% | |
| 15.0444% | |
| -18.2907% | |
| 93.2647% | |
| 26.5446% | |
| 23.1972% | |
| 9.4946% | |
| 42.3497% | |
| 16.3552% | |
| 21.6365% | |
| 33.5911% | |
| -28.2365% | |
| 31.5364% | |
| 20.1143% | |
| 42.7636% | |
| 42.7175% | |
| -19.161% | |
| -38.6503% | |
| -26.5743% | |
| 53.6265% | |
| -20.2709% | |
| 43.6442% | |
| -17.0039% | |
| -20.1247% | |
| 17.4619% | |
| -26.1772% | |
| 47.8538% | |
| 2.3741% | |
| 10.3554% | |
| 21.5714% | |
| 0.3029% | |
| -5.2728% | |
| 13.306% | |
| -5.7594% | |
| -9.2608% | |
| -1.8024% | |
| -26.6335% | |
| 31.8155% | |
| -14.309% | |
| 28.5862% | |
| -56.3603% |